RAND Corporation, 4570 Fifth Avenue, Suite 600, Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, PA, USA.
Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
Drug Alcohol Depend. 2021 Apr 1;221:108569. doi: 10.1016/j.drugalcdep.2021.108569. Epub 2021 Feb 3.
Prescribing naloxone to patients at increased opioid overdose risk is a key component of opioid overdose prevention efforts, but little is known about naloxone fills among patients receiving buprenorphine for opioid use disorder, one such high risk group.
This retrospective cross-sectional study used de-identified pharmacy claims representing 90% of all prescriptions filled at retail pharmacies in 50 states and the District of Columbia. We performed a multivariable logistic regression to examine filled naloxone prescriptions among patients receiving buprenorphine treatment and assessed how filled naloxone prescriptions vary by patient, prescriber, and community characteristics.
Filled naloxone prescriptions occurred among 4.5% of buprenorphine treatment episodes. Episodes paid through Medicaid (aOR 2.40, 95%CI 2.33-2.47) and Medicare (aOR 1.53, 95%CI 1.46-1.60) had higher odds of filled naloxone prescriptions than commercial insurance episodes. Compared to episodes where the primary prescriber was an adult primary care physician, odds of filling a naloxone prescription were higher among episodes prescribed by addiction specialists (aOR 1.30, 95% CI 1.24-1.37) and physician assistants/nurse practitioners (aOR 1.57, 95% CI 1.53-1.61).
Prescribing naloxone to patients receiving buprenorphine represents a tangible clinical action that can be taken to help prevent opioid overdose deaths. However, despite recommendations to co-prescribe naloxone to patients at increased risk for opioid overdose, rates of filling naloxone prescriptions remain low among patients dispensed buprenorphine. States, insurers, and health systems should consider implementing strategies to facilitate increased co-prescribing of naloxone to at-risk individuals.
为有较高阿片类药物过量风险的患者开具纳洛酮处方是阿片类药物过量预防工作的一个关键组成部分,但对于接受丁丙诺啡治疗阿片类药物使用障碍的患者(高危人群之一),他们开出的纳洛酮处方数量知之甚少。
本回顾性横断面研究使用了来自全美 50 个州和哥伦比亚特区的零售药店 90%的处方记录,这些处方均经过去标识处理。我们进行了多变量逻辑回归分析,以研究接受丁丙诺啡治疗的患者中开出的纳洛酮处方情况,并评估了纳洛酮处方的开具情况如何因患者、处方医生和社区特征而有所不同。
有 4.5%的丁丙诺啡治疗疗程中开出了纳洛酮处方。与商业保险相比,通过医疗补助(调整后的优势比[aOR]2.40,95%置信区间[CI]2.33-2.47)和医疗保险(aOR 1.53,95%CI 1.46-1.60)支付的疗程开出纳洛酮处方的可能性更高。与主要处方医生为成人初级保健医生的疗程相比,由成瘾专科医生(aOR 1.30,95%CI 1.24-1.37)和医生助理/执业护士(aOR 1.57,95%CI 1.53-1.61)开出纳洛酮处方的可能性更高。
为接受丁丙诺啡治疗的患者开具纳洛酮处方是一项切实可行的临床措施,有助于预防阿片类药物过量死亡。尽管建议为有较高阿片类药物过量风险的患者共同开具纳洛酮处方,但开出纳洛酮处方的比例仍然很低。各州、保险公司和医疗系统应考虑实施相关策略,以促进为高危个体共同开具纳洛酮处方。